Abstract: A pharmaceutical composition suitable for preventing or treating cardiac arrhythmia is disclosed. The pharmaceutical composition contains, as an active ingredient, a CCN5 protein or a nucleotide encoding the CCN5 protein. The pharmaceutical composition inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities that is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition can be effectively used in the prevention or treatment of cardiac arrhythmia.

Abstract: The present invention relates to a composition comprising a protein phosphatase 1 inhibitory peptide for treating vascular diseases. The composition of the present invention inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation to suppress abnormal proliferation of vascular smooth muscle cells (VSMCs), and activates eNOS of vascular endothelial cells (VECs) to induce the recovery from dysfunction, and thus can be favorably used in the treatment of vascular diseases including pulmonary hypertension.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cardiac arrhythmia. Particularly, the present invention relates to a pharmaceutical composition containing, as an active ingredient, a CCN5 protein or a nucleotide encoding the same. The pharmaceutical composition for preventing or treating cardiac arrhythmia, of the present invention, inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities which is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition of the present invention can be effectively used in the prevention or treatment of cardiac arrhythmia.

Abstract: The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein.

Abstract: The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X1-Ala-X2-X3-Ile-Glu-X4 (I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of cardiac fibrosis or heart diseases accompanied by cardiac fibrosis. According to the present invention, the composition of the present invention has an effect of dissolving a fibrosis matrix and performing restoration to normal tissues by selectively destroying myofibroblasts in cardiac fibrosis which is diagnosed after a disease occurs, and therefore can be usefully used as a composition for the treatment of cardiac fibrosis, systolic heart failure and diastolic heart failure for which a therapeutic agent has not been developed due to being considered as an irreversible disease progression up to date.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a heart failure and a method for screening a therapeutic agent for preventing or treating a heart failure. The pharmaceutical composition of the present disclosure comprises the CCN5 or CCN2?CT protein, or a genetic carrier comprising a nucleotide sequence encoding the CCN5 or the CCN2?CT protein, exhibiting dramatic prevention or treatment efficacies on a heart failure even without surgical treatments accompanied with transplanting a donor heart.

Abstract: The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X1-Ala-X2—X3-Ile-Glu-X4 (I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.